Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on long-term LDL apheresis treatment

Banyai, S; Borggrefe, Martin; Falger, Janne M.; Jansen, M.; Alt, Elisabeth; Derfler, Kurt; Koppensteiner, Renate

doi:10.1016/s0021-9150(01)00532-9

Cited by 39 publications

(17 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Platelet Surface CD 63 Expression After Stimulation with ADP and TRAP let aggregation (28). A more important reason is the coadministration of clopidogrel in our study.…”

Section: Discussionmentioning

confidence: 71%

Treatment With Ezetimibe Plus Low-Dose Atorvastatin Compared With Higher-Dose Atorvastatin Alone

Piorkowski

Fischer

Stellbaum

et al. 2007

Journal of the American College of Cardiology

View full text Add to dashboard Cite

show abstract

“…Platelet Surface CD 63 Expression After Stimulation with ADP and TRAP let aggregation (28). A more important reason is the coadministration of clopidogrel in our study.…”

Section: Discussionmentioning

confidence: 71%

Treatment With Ezetimibe Plus Low-Dose Atorvastatin Compared With Higher-Dose Atorvastatin Alone

Piorkowski

Fischer

Stellbaum

et al. 2007

Journal of the American College of Cardiology

View full text Add to dashboard Cite

show abstract

“…A prior study in 12 patients with familial hypercholesterolemia on regular LDL-apheresis suggested that atorvastatin may improve blood rheology [3]. In a study of Bolaman et al [5] atorvastatin did not significantly change levels of hemoglobin, nor the number of white blood cells and platelets.…”

Section: Discussionmentioning

confidence: 93%

High-dose atorvastatin treatment in patients with peripheral arterial disease: Effects on platelet aggregation, blood rheology and plasma homocysteine

Loo

Spring

Koppensteiner

2011

Clinical Hemorheology and Microcirculation

View full text Add to dashboard Cite

Background: Statins are used for the treatment of hypercholesterolemia. Although they are well known to have pleiotropic effects, their dose-dependent influence on platelet aggregation, hemorheologic properties and the plasma levels of homocysteine in patients with peripheral arterial disease (PAD) has not been thoroughly investigated so far.Methods and results: From a total of 100 patients with PAD 48 patients were randomized to a treatment with atorvastatin 80 mg/d for six months, and 52 patients served as controls who continued their medication including statins in lower doses. At baseline and at six months' follow up we assessed platelet aggregation upon stimulation with ADP, collagen and epinephrine using light transmission aggregometry. Furthermore, we determined major hemorheologic variables as well as the plasma levels of homocysteine, folic acid, and vitamin B6 and B12. No patient had obtained folic acid or B vitamin supplement.Platelet aggregation upon agonist-induced stimulation did not differ between patients under high-dose atorvastatin therapy and controls at baseline and after six months (p > 0.05). All hemorheologic parameters (plasma viscosity, red cell aggregation, whole blood viscosity, hematocrit, platelets, leucocytes) measured at baseline and after six months were not significantly different between both groups, too. After therapy with 80 mg atorvastatin homocysteine levels were significantly elevated as compared with baseline values (p = 0.0007), whereas levels remained unchanged in the control group. Folic acid levels were higher in the patients receiving high-dose atorvastatin as compared with controls both at baseline (p = 0.002) and at six months' follow up (p = 0.034). No significant difference in vitamin B6 and B12 levels both at baseline and after six months could be detected in either group.Conclusions: Treatment with 80 mg atorvastatin did not affect platelet aggregation and major hemorheologic parameters. The finding of an increase of homocysteine plasma levels in the presence of rather elevated levels of folic acid needs further investigation.

show abstract

“…These medications could have an effect on the aggregation of the cells and they include both aspirin [28], thienopyridines [29,30] as well as statins [31,32]. However, since most of our patients, and in especially in the ACS group, were treated with at least one of these medications, we could not isolate this potential effect on our results.…”

Section: Discussionmentioning

confidence: 99%

Erythrocyte aggregation as a cause of slow flow in patients of acute coronary syndromes

Arbel

Banai

Benhorin

et al. 2012

International Journal of Cardiology

View full text Add to dashboard Cite

Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on long-term LDL apheresis treatment

Cited by 39 publications

References 40 publications

Treatment With Ezetimibe Plus Low-Dose Atorvastatin Compared With Higher-Dose Atorvastatin Alone

Treatment With Ezetimibe Plus Low-Dose Atorvastatin Compared With Higher-Dose Atorvastatin Alone

High-dose atorvastatin treatment in patients with peripheral arterial disease: Effects on platelet aggregation, blood rheology and plasma homocysteine

Erythrocyte aggregation as a cause of slow flow in patients of acute coronary syndromes

Contact Info

Product

Resources

About